Looking forward to ICPE in Berlin!
The DSRU team will be attending the 40th International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE) in Berlin on 24-28th August.
The wide variety of observational studies that we conduct, both at the DSRU and via a number of collaborations, will be presented in 6 research posters. Dr Debabrata Roy will present a case series analysis of thromboembolic events from our major post authorisation safety study on a Covid-19 vaccine that was completed early in 2024.
The DSRU will also have a booth (#202) in the exhibition, which will showcase our capabilities as the UK’s leading unit for pharmacovigilance and pharmacoepidemiology. We offer a range of real-world observational studies including drug utilisation studies, CPRD studies, registries (including EAMS) and a pharmacoepidemiology and real-world service for small and medium companies. We also conduct multi-database network studies across Europe (the DSRU is a member of the VAC4EU consortium group).
If you are attending ICPE conference, do come and say hello! Members of the DSRU team would be delighted to discuss our capabilities and our research posters with you.
Discover the breadth of DSRU research and expertise via our posters and oral presentation at ICPE Berlin:
Our Oral Presentation:
Wednesday 28th August
Case Series Analysis of Thromboembolic Events (Arterial and Venous) in Vaccinees Following AZD1222 (ChAdOx1nCoV-19): Results from a UK Post-authorisation Active Surveillance Study. M. Davies, S. Dhanda, A. Evans, D. Roy, S. Shakir
Our Posters:
Tuesday 27th August
(344) Interim results from the VAC4EU Post-Authorization Safety Study (PASS) among recipients of the Pfizer-BioNTech COVID-19 (Comirnaty®) vaccine in Europe. D. Weibel, C. De Luise, A. Cid Royo, O. Ryan, T. Vaz, J. Aguado, J. Marsal, X. Garcia De Albeniz Martinez, R. Weinrib, N. Yefimenko, E. Palà, B. Poblador-Plou, A. Gimeno-Miguel, A. Santos-Mejías, E. Marconi, E. Barbieri, L. Stona, T. Lysen, D. Roy, G. Hyeraci, A. Garardi, A. Lupattelli, A. Assefa Desalegn, F. Villalobos, C. Alberto Bissacco, K. Kendrick, R. Garg, H. Rubino, M. C.J.M. Sturkenboom, A. Arana
(367) VAC4EU study to identify risk factors and characterize the clinical course of myocarditis/pericarditis following mRNA-1273 vaccination in four European countries: first descriptive analyses. L. C. Zwiers, B. M. Goodale, F. M. A. Van Der Velden, S. St. Laurent, D. B. Esposito, L. Zhu, V. V. Urdaneta, D. Martin, M. Emilebacker, D. Weibel, A. Lupattelli, A. Assefa Desalegn, F. Villalobos, C. Alberto Bissacco, J. José Carreras, A. Urchueguía-Fornes, E. Correcher, C. M. Fry, D. Morris, T. Aurelius, S. Lane, D. Roy, L. Wang, V. Ehrenstein, D. Grobbe, D. Ong
Wednesday 28th August
(037) The public health impact of suspending cyproterone acetate (2mg)/ ethinylestradiol ((35µg) in France: A predictive modelling technique to estimate adverse drug reactions prevented by regulatory action. [1230] S. Lane, A. Bobbins, S. Shakir, E. Lynn
(333) Case Series Analysis of Immune-Mediated Neurological Events in Vaccinees following AZD1222 (ChAdOx1nCoV-19): Results from a UK Post-authorisation Active Surveillance Study. [1523] S. Dhanda, M. Davies, A. Evans, S. Shakir, D. Roy
(338) Cumulative Rates of Serious and Adverse Events of Special Interest in Vaccinees Following AZD1222 (ChAdOx1nCoV-19): Results from a UK Post-authorisation Active Surveillance Study. [1528] A. Evans, M. Davies, S. Dhanda, S. Shakir, D. Roy
(349) Observed versus Expected Analysis of Adverse Events of Special Interest after AZD1222 (ChAdOx1nCoV-19) Vaccination: Results from a UK Post-authorisation Active Surveillance Study. [1539] A. Evans, D. Roy, M. Davies, S. Dhanda, S. Shakir